This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

Schizophrenia International Research Society

March 29^th – April 2^nd 2025, Chicago, IL

Explore materials from this congress

PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.

Schizophrenia

ENCORE POSTER

Acute and Maintenance Treatment Effects of Olanzapine/Samidorphan on Negative Symptoms in Patients With Acute Schizophrenia: A Post Hoc Analysis

AUTHOR(S)

Roger S. McIntyre,¹ Desiree M. Matthews,² Marni E. Harris,³ Christina Arevalo,³ Martin Dunbar,³ David McDonnell,⁴ Christoph U. Correll^5-7

View poster

Schizophrenia

ENCORE POSTER

Baseline Severity of Illness and Response to Treatment With Aripiprazole Lauroxil Every 2 Months: A Post Hoc Analysis of Phase 3 ALPINE Clinical Trial Data

AUTHOR(S)

John M. Kane, MD¹ ; Martin Dunbar, PhD² ; and James A. McGrory, PhD²

View poster

Schizophrenia

ENCORE POSTER

Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia

AUTHOR(S)

Andrew J. Cutler, MD,^1,2 Hemangi R. Panchmatia, MSc,³ Alejandro G. Hughes, MPH,⁴ Michael J. Doane, PhD,³ Hara E. Oyedeji, CRNP, MS,⁵ Rakesh Jain, MD, MPH⁶

View poster

Schizophrenia

Bipolar Disorder

Schizophrenia

POSTER

Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study

AUTHOR(S)

Jacob S. Ballon, MD, MPH,¹ Christina Arevalo, MS,² Martin Dunbar, PhD,² Alexandra Lovett, MD,² David McDonnell, MD,³ Christoph U. Correll, MD^4-7

View poster

Bipolar Disorder

Schizophrenia

Bipolar Disorder

Schizophrenia

ENCORE POSTER

Study Retention Rates in the OLZ/SAM Phase 3 Clinical Program

AUTHOR(S)

René S. Kahn,¹ Christina Arevalo,² Marni E. Harris,² David McDonnell³

View poster

Bipolar Disorder

Schizophrenia

ENCORE POSTER

Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen

AUTHOR(S)

Lauren N. Strand, PhD, MS¹ ; Michael J. Doane, PhD¹ ; James A. McGrory, PhD¹ ; Alejandro G. Hughes, MPH² ; John Lauriello, MD³

View poster

Schizophrenia

Welcome to Alkermes Medical Affairs

Message Sent

Sent

This selection will navigate away from Alkermes Medical Affairs.